MedTrace Logo

Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

NCT06327815 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 633

Last updated 2025-10-31

No results posted yet for this study

Summary

Study D1690L00149 is a 24-week, multicentre, randomized, parallel, interventional, non-inferiority, open-label study designed to compare the FDC Regimen of Dapagliflozin/Metformin XR with the Dapagliflozin co-administered with Metformin XR in glycemic lowering control, satisfaction and adherence in Chinese patients with T2DM.

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets

10 mg Dapagliflozin/1000 mg Metformin HCl extended-release

DRUG

Dapagliflozin tablets and Metformin HCl extended-release tablets

Dapagliflozin tablets: 10 mg Metformin HCl extended-release tablets: 1000 mg

Sponsors & Collaborators

Principal Investigators

  • Guang Wang · Beijing Chao Yang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06327815 on ClinicalTrials.gov